One-Year Outcomes following Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy in Japanese Patients: The APOLLO Study
One-Year Outcomes following Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy in Japanese Patients: The APOLLO Study
复制标题
DOI：
10.1159/000477448
复制
发表时间：
2017-01-01
期刊：
影响因子：
2.6
通讯作者：
Ishibashi, Tatsuro
中科院分区：
文献类型：
--
作者：
Oshima, Yuji;Kimoto, Kenichi;Ishibashi, Tatsuro
目的：评价玻璃体内注射阿柏西普（IVA）治疗日本息肉状脉络膜血管病变（PCV）患者的1年结局。研究方法：在这项前瞻性、开放标签、单臂多中心临床试验中，首次接受PCV治疗的患者在3次初始每月给药后，每2个月接受一次IVA（2.0 mg）。评估的主要终点是1年时维持基线最佳矫正视力（BCVA）的患者比例。结果：50只患眼均为PCV。97.6%的患者BCVA维持或改善。基线时的平均logMAR BCVA为0.33，在开始阿柏西普治疗后1年改善至0.12 logMAR（p <0.001）。治疗1年后，72.5%的息肉样病变完全消退。结论：一年的IVA导致日本PCV患者的BCVA稳定和解剖结构改善。(c)2017 S. Karger AG，巴塞尔
Purpose: To evaluate 1-year outcomes of intravitreal injections of aflibercept (IVA) in Japanese polypoidal choroidal vasculopathy (PCV) patients. Methods: In this prospective, open-label, single-arm multicenter clinical trial, treatment-naive PCV patients received IVA (2.0 mg) every 2 months, after 3 initial monthly doses. The primary endpoint assessed was the proportion of patients maintaining baseline best-corrected visual acuity (BCVA) at 1 year. Results: Fifty eyes with PCV were included in the study. BCVA was maintained or improved in 97.6% of the patients. Mean logMAR BCVA at baseline was 0.33, and had improved to 0.12 logMAR 1 year after the initiation of aflibercept treatment (p < 0.001).Mean central foveal thickness decreased from 356 to 239 mu m (p < 0.001). Complete regression of polypoidal lesions was seen in 72.5% after 1 year of treatment. Conclusions: One year of IVA resulted in stabilization of BCVA and anatomical improvement in Japanese PCV patients. (c) 2017 S. Karger AG, Basel